BACKGROUND: The aim of this study was to evaluate the impact of the interval between diagnosis and treatment using radiofrequency (RF) ablation on the survival of patients with HCC detected through a surveillance program. METHODS: Between January 2004 and July 2007, 121 cirrhotic patients with 157 tumours detected through a surveillance program underwent RF ablation. A delay in treatment was defined as >5 weeks. The mean length of follow-up was 25 months (range 8-55 months). Cumulative survival of patients was analysed using the Kaplan-Meier method. Cox regression models were used to identify factors associated with patient survival. RESULTS: The 1-, 2- and 3-year survival rates were 92.5%, 78.5% and 67.2%. The independent predictors of poorer patient survival were time from diagnosis to treatment >5 weeks (pooled odds ratio [OR], 3.59; 95% confidence interval [CI], 1.58-8.18; P = 0.002), absence of complete ablation after the initial RF session (OR, 2.42; 95% CI 1.07-5.45; P = 0.033) and Child-Pugh B liver cirrhosis (OR, 2.46; 95% CI 1.06-5.70; P = 0.036). CONCLUSIONS: Delay in the start of effective treatment for HCC using RF ablation may be associated with poorer patient survival.
BACKGROUND: The aim of this study was to evaluate the impact of the interval between diagnosis and treatment using radiofrequency (RF) ablation on the survival of patients with HCC detected through a surveillance program. METHODS: Between January 2004 and July 2007, 121 cirrhotic patients with 157 tumours detected through a surveillance program underwent RF ablation. A delay in treatment was defined as >5 weeks. The mean length of follow-up was 25 months (range 8-55 months). Cumulative survival of patients was analysed using the Kaplan-Meier method. Cox regression models were used to identify factors associated with patient survival. RESULTS: The 1-, 2- and 3-year survival rates were 92.5%, 78.5% and 67.2%. The independent predictors of poorer patient survival were time from diagnosis to treatment >5 weeks (pooled odds ratio [OR], 3.59; 95% confidence interval [CI], 1.58-8.18; P = 0.002), absence of complete ablation after the initial RF session (OR, 2.42; 95% CI 1.07-5.45; P = 0.033) and Child-Pugh B liver cirrhosis (OR, 2.46; 95% CI 1.06-5.70; P = 0.036). CONCLUSIONS: Delay in the start of effective treatment for HCC using RF ablation may be associated with poorer patient survival.
Authors: Sergio Muñoz-Martínez; Victor Sapena; Alejandro Forner; Jean-Charles Nault; Gonzalo Sapisochin; Lorenza Rimassa; Bruno Sangro; Jordi Bruix; Marco Sanduzzi-Zamparelli; Wacław Hołówko; Mohamed El Kassas; Tudor Mocan; Mohamed Bouattour; Philippe Merle; Frederik J H Hoogwater; Saleh A Alqahtani; Helen L Reeves; David J Pinato; Emmanouil Giorgakis; Tim Meyer; Gerda Elisabeth Villadsen; Henning Wege; Massimiliano Salati; Beatriz Mínguez; Giovan Giuseppe Di Costanzo; Christoph Roderburg; Frank Tacke; María Varela; Peter R Galle; Mario Reis Alvares-da-Silva; Jörg Trojan; John Bridgewater; Giuseppe Cabibbo; Christian Toso; Anja Lachenmayer; Andrea Casadei-Gardini; Hidenori Toyoda; Tom Lüdde; Rosanna Villani; Ana María Matilla Peña; Cassia Regina Guedes Leal; Monica Ronzoni; Manuel Delgado; Christie Perelló; Sonia Pascual; José Luis Lledó; Josepmaria Argemi; Bristi Basu; Leonardo da Fonseca; Juan Acevedo; Alexander R Siebenhüner; Chiara Braconi; Brandon M Meyers; Alessandro Granito; Margarita Sala; Carlos Rodríguez-Lope; Lorraine Blaise; Manuel Romero-Gómez; Federico Piñero; Dhanny Gomez; Vivianne Mello; Rogerio Camargo Pinheiro Alves; Alex França; Fernanda Branco; Giovanni Brandi; Gustavo Pereira; Susanna Coll; Maria Guarino; Carlos Benítez; Maria Margarita Anders; Juan C Bandi; Mercedes Vergara; Mariona Calvo; Markus Peck-Radosavljevic; Ignacio García-Juárez; Vincenzo Cardinale; Mar Lozano; Martina Gambato; Stefano Okolicsanyi; Dalia Morales-Arraez; Alessandra Elvevi; Alberto E Muñoz; Alberto Lué; Massimo Iavarone; Maria Reig Journal: JHEP Rep Date: 2021-02-23
Authors: Rajalakshmi Govalan; Michael Luu; Marie Lauzon; Kambiz Kosari; Joseph C Ahn; Nicole E Rich; Nicholas Nissen; Lewis R Roberts; Amit G Singal; Ju Dong Yang Journal: Hepatol Commun Date: 2021-08-25
Authors: M Brugel; O Bouché; R Kianmanesh; L Teuma; A Tashkandi; J M Regimbeau; P Pessaux; B Royer; R Rhaiem; C Perrenot; C Neuzillet; T Piardi; S Deguelte Journal: BMC Surg Date: 2021-12-07 Impact factor: 2.102